Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Evolus, Inc. - Common Stock (NQ:EOLS)

7.210 +0.070 (+0.98%)
Delayed Quote Updated: 9:55 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Evolus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Evolus to Report Second Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
News headline image
Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”
From Evolus
Via Business Wire
News headline image
Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
News headline image
Needham Is Bullish On This Botox Equivalent Aesthetics Company ↗
 
Via Benzinga
News headline image
Recap: Evolus Q4 Earnings ↗
Evolus (NASDAQ:EOLS) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus missed... 
Via Benzinga
News headline image
A Preview Of Evolus's Earnings ↗
Evolus (NASDAQ:EOLS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Evolus's Return On Capital Employed Overview ↗
According to data from Benzinga Pro, during Q1, Evolus's (NASDAQ:EOLS) reported sales totaled $33.91 million. Despite a 3.72% increase in earnings, the company posted a loss of $17.50 million. 
Via Benzinga
News headline image
Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed
From Evolus
Via Business Wire
News headline image
Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States
From Evolus
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Evolus to Participate in the H.C. Wainwright Global Investment Conference
From Evolus
Via Business Wire
News headline image
Evolus: Q1 Earnings Insights ↗
Evolus (NASDAQ:EOLS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Evolus beat estimated earnings by 6.06%,... 
Via Benzinga
News headline image
Evolus Reports First Quarter 2022 Results and Provides Business Update
From Evolus
Via Business Wire
News headline image
Evolus to Report First Quarter 2022 Results and Provide Business Update
From Evolus
Via Business Wire
News headline image
Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®
From Evolus
Via Business Wire
News headline image
EVOLUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Evolus, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Evolus's Return On Capital Employed Insights ↗
According to Benzinga Pro data, during Q4, Evolus (NASDAQ:EOLS) posted sales of $34.66 million. Earnings were up 6.46%, but Evolus still reported an overall loss of $18.18 million... 
Via Benzinga
News headline image
Evolus Reports Narrower Q4 Loss, CFO Retires, Reaffirms FY22 Outlook ↗
Evolus Inc's (NASDAQ: EOLS) Q4 FY21 sales increased 68% Y/Y to $34.7 million in line with interim results, beating the consensus of $33.99 million, driven... 
Via Benzinga
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
News headline image
Evolus to Report Fourth Quarter and Year End 2021 Results and Provide Business Update
From Evolus
Via Business Wire
News headline image
Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®
From Evolus
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Nuvectis Pharma (NASDAQ:NVCT) stock moved upwards by 132.3% to $7.55 during Monday's regular session. The current volume of 17.0 million shares is 2307.5% of... 
Via Benzinga
News headline image
Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference
From Evolus, Inc.
Via Business Wire
News headline image
41 Biggest Movers From Yesterday ↗
Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed the Federal Reserve Reserve decision to leave... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Rani Therapeutics Hldgs (NASDAQ:RANI 
Via Benzinga
News headline image
Evolus Expects Q4 FY21 Sales Better Than Anticipated, Issues FY22 Guidance ↗
Evolus Inc (NASDAQ: EOLS) has posted interim Q4 sales of approximately $34.7 million (better than the consensus of $30.87 million), up 68% Y/Y, driven by higher... 
Via Benzinga
News headline image
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance
From Evolus, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2022 ↗
Upgrades For W.P. Carey Inc (NYSE:WPC), B... 
Via Benzinga
News headline image
Evolus Expands Board of Directors With Appointment of Digital and Beauty Innovator Brady Stewart
From Evolus
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.